These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38142783)

  • 1. Repurposing of FDA approved kinase inhibitor bosutinib for mitigation of radiation induced damage via inhibition of JNK pathway.
    Singh B; Patwardhan RS; Pal D; Maurya DK; Singh BG; Checker R; Sharma D; Sandur SK
    Toxicol Appl Pharmacol; 2024 Jan; 482():116792. PubMed ID: 38142783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosutinib treatment for Philadelphia chromosome-positive leukemias.
    Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ
    Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.
    Abbas R; Hsyu PH
    Clin Pharmacokinet; 2016 Oct; 55(10):1191-1204. PubMed ID: 27113346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Hu S; Xie D; Zhou P; Liu X; Yin X; Huang B; Guan H
    Int J Mol Med; 2021 May; 47(5):. PubMed ID: 33693953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
    Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
    Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
    Tarpley M; Abdissa TT; Johnson GL; Scott JE
    Anticancer Res; 2014 Apr; 34(4):1629-35. PubMed ID: 24692691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Akt1/NFκB signaling pathway activation by a small molecule DMA confers radioprotection to intestinal epithelium in xenograft model.
    Tiwari V; Kamran MZ; Ranjan A; Nimesh H; Singh M; Tandon V
    Free Radic Biol Med; 2017 Jul; 108():564-574. PubMed ID: 28435051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
    Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
    Daud AI; Krishnamurthi SS; Saleh MN; Gitlitz BJ; Borad MJ; Gold PJ; Chiorean EG; Springett GM; Abbas R; Agarwal S; Bardy-Bouxin N; Hsyu PH; Leip E; Turnbull K; Zacharchuk C; Messersmith WA
    Clin Cancer Res; 2012 Feb; 18(4):1092-100. PubMed ID: 22179664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
    Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
    Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
    Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
    Wermuth PJ; Jimenez SA
    PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
    Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
    Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.
    Boschelli F; Arndt K; Gambacorti-Passerini C
    Eur J Cancer; 2010 Jul; 46(10):1781-9. PubMed ID: 20399641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
    Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
    Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.